depression

News

Is AbbVie planning an epic Gilgamesh takeover?

AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.

News

Beckley psychedelic hits the target, unlocking atai merger

The proposed merger between Beckley Psytech and atai can go ahead as a psychedelic for depression hits all its endpoints in a phase 2b trial.

News

App to support people with depression launches in GB

A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.

News

rofessor John Atack and Professor Simon Ward, from Cardiff University’s Medicines Discovery Institute

Welsh biotech Draig emerges with $140m in financing

Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.

News

Consolidation in psychedelics as atai pairs with Beckley

Beckley Psytech has agreed to merge with atai Life Sciences in a deal that would bring together two psychedelic medicine pioneers.

News

Beckley Psytech's chief scientific and medical officer Dr Rob Conley

Beckley's psychedelic med inches forward in depression

UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.

Is AbbVie planning an epic Gilgamesh takeover?

Beckley psychedelic hits the target, unlocking atai merger

App to support people with depression launches in GB

Welsh biotech Draig emerges with $140m in financing

Consolidation in psychedelics as atai pairs with Beckley

Beckley's psychedelic med inches forward in depression

CHMP backs Novo's haemophilia A drug Frehemgo

Discover a new era of healthcare panel engagement: Grounded ...

depression

Editor's Picks